O-GlcNacylation Links TxNIP to Inflammasome Activation in Pancreatic β Cells.
O-GlcNAcylation
TXNIP (thioredoxin-interacting protein)
hyperglycemia
inflammasome
pancreatic beta cells
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
01
2019
accepted:
23
04
2019
entrez:
6
6
2019
pubmed:
6
6
2019
medline:
6
6
2019
Statut:
epublish
Résumé
Thioredoxin interacting protein (TxNIP), which strongly responds to glucose, has emerged as a central mediator of glucotoxicity in pancreatic β cells. TxNIP is a scaffold protein interacting with target proteins to inhibit or stimulate their activity. Recent studies reported that high glucose stimulates the interaction of TxNIP with the inflammasome protein NLRP3 (NLR family, pyrin domain containing 3) to increase interleukin-1 β (IL1β) secretion by pancreatic β cells. To better understand the regulation of TxNIP by glucose in pancreatic β cells, we investigated the implication of O-linked β-N-acetylglucosamine (O-GlcNAcylation) in regulating TxNIP at the posttranslational level. O-GlcNAcylation of proteins is controlled by two enzymes: the O-GlcNAc transferase (OGT), which transfers a monosaccharide to serine/threonine residues on target proteins, and the O-GlcNAcase (OGA), which removes it. Our study shows that TxNIP is subjected to O-GlcNAcylation in response to high glucose concentrations in β cell lines. Modification of the O-GlcNAcylation pathway through manipulation of OGT or OGA expression or activity significantly modulates TxNIP O-GlcNAcylation in INS1 832/13 cells. Interestingly, expression and O-GlcNAcylation of TxNIP appeared to be increased in islets of diabetic rodents. At the mechanistic level, the induction of the O-GlcNAcylation pathway in human and rat islets promotes inflammasome activation as evidenced by enhanced cleaved IL1β. Overexpression of OGT in HEK293 or INS1 832/13 cells stimulates TxNIP and NLRP3 interaction, while reducing TxNIP O-GlcNAcylation through OGA overexpression destabilizes this interaction. Altogether, our study reveals that O-GlcNAcylation represents an important regulatory mechanism for TxNIP activity in β cells.
Identifiants
pubmed: 31164864
doi: 10.3389/fendo.2019.00291
pmc: PMC6536593
doi:
Types de publication
Journal Article
Langues
eng
Pagination
291Références
Endocrinology. 2002 Sep;143(9):3695-8
pubmed: 12193586
Mol Pharmacol. 2005 Apr;67(4):1206-13
pubmed: 15630078
Endocrinology. 2005 May;146(5):2397-405
pubmed: 15705778
Nature. 2007 Apr 26;446(7139):1017-22
pubmed: 17460662
Diabetes. 2008 Apr;57(4):938-44
pubmed: 18171713
FASEB J. 2008 Oct;22(10):3581-94
pubmed: 18552236
Biochem Pharmacol. 2008 Oct 1;76(7):873-83
pubmed: 18718450
Trends Endocrinol Metab. 2008 Dec;19(10):380-9
pubmed: 18929495
J Biol Chem. 2009 Feb 6;284(6):3425-32
pubmed: 19073609
Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E17-27
pubmed: 19843875
Nat Immunol. 2010 Feb;11(2):136-40
pubmed: 20023662
Science. 2010 Jan 15;327(5963):296-300
pubmed: 20075245
Transplantation. 2010 May 15;89(9):1154-60
pubmed: 20098354
Cell Signal. 2010 Aug;22(8):1240-6
pubmed: 20385228
Diabetes. 2010 Jul;59(7):1845-50
pubmed: 20413512
Diabetes. 2011 May;60(5):1399-413
pubmed: 21471514
J Biol Chem. 2011 Nov 4;286(44):38027-34
pubmed: 21908621
Clin Chim Acta. 2012 Aug 16;413(15-16):1163-70
pubmed: 22521751
J Immunol. 2012 Sep 1;189(5):2131-7
pubmed: 22815289
Cell Metab. 2012 Aug 8;16(2):265-73
pubmed: 22883234
Methods Mol Biol. 2012;933:125-59
pubmed: 22893405
J Clin Endocrinol Metab. 2012 Dec;97(12):4640-9
pubmed: 23066116
J Mol Endocrinol. 2012 Dec 31;50(1):59-71
pubmed: 23152583
Mol Cell. 2013 Mar 28;49(6):1167-75
pubmed: 23453806
J Biol Chem. 2013 Aug 9;288(32):23194-202
pubmed: 23803610
Nat Med. 2013 Sep;19(9):1141-6
pubmed: 23975026
FASEB J. 2014 Feb;28(2):1010-21
pubmed: 24174424
Mol Endocrinol. 2014 Aug;28(8):1211-20
pubmed: 24911120
Basic Res Cardiol. 2014;109(5):415
pubmed: 25015733
Front Endocrinol (Lausanne). 2014 Dec 01;5:206
pubmed: 25520704
Redox Biol. 2015;4:296-307
pubmed: 25625584
Nutr Hosp. 2014 Sep 12;31(3):1129-33
pubmed: 25726203
Nat Med. 2015 May;21(5):512-7
pubmed: 25894829
Methods Mol Biol. 2016;1417:89-95
pubmed: 27221483
Cancer Cell. 2016 Aug 8;30(2):290-307
pubmed: 27505673
Nat Rev Mol Cell Biol. 2017 Jul;18(7):452-465
pubmed: 28488703
Cell Rep. 2017 Jun 6;19(10):2005-2013
pubmed: 28591573
PLoS Pathog. 2017 Jul 24;13(7):e1006518
pubmed: 28742148
Cell Rep. 2017 Aug 1;20(5):1088-1099
pubmed: 28768194
Exp Clin Endocrinol Diabetes. 2018 Jun 11;:null
pubmed: 29890544
Diabete Metab. 1995 Dec;21(5):365-70
pubmed: 8586154